Pembrolizumab Plus B-Cell Receptor Inhibitors Generates Response in Richter Transformation of CLL/SLL
The addition of a B-cell receptor (BCR) inhibitor to pembrolizumab (Keytruda) led to responses in patients with Richter transformation of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to data from a phase 2 trial ( …